Gallagher, Mary PatRompicherla, SakethEbekozien, OsagieWilkes, MeredithAntal, ZoltanFeuer, Alexis JamieRioles, NicoleNoor, NudratGabriel, LianaO’Malley, GrenyeGolden, LaurenAlonso, G. ToddOspelt, EmmaOdugbesan, OriLyons, Sarah K.Mungmode, AnnPrahalad, PriyaClements, MarkNeyman, AnnaDemeterco-Berggren, CarlaRapaport, Robert2023-03-222023-03-222022-01Gallagher MP., et al. (2022). Differences in COVID-19 Outcomes Among Patients With Type 1 Diabetes: First vs Later Surges. Journal of Clinical Outcomes Management, 29(1). https://doi.org/10.12788/jcom.0084https://hdl.handle.net/1805/32031Background Outcomes of the novel coronavirus SARS-CoV-2 (COVID-19) have improved throughout the pandemic. However, whether outcomes of COVID-19 in the type 1 diabetes (T1D) population improved over time is unknown. Therefore, we aim to investigate differences in COVID-19 outcomes for patients with T1D in the US. Method We analyzed data collected via a registry of patients with T1D and COVID-19 from 56 sites between April 2020 and January 2021. First, we grouped cases into First Surge (04/09/2020 - 07/31/2020, n=188) and Late Surge (08/01/2020 - 01/31/2021, n=410). Then, we compared outcomes between both groups using descriptive statistics and logistic regression models. Results Adverse outcomes were more frequent during the first surge including Diabetic Ketoacidosis (32% versus 15%, p<0.001), severe hypoglycemia (4% versus 1%, p=0.04) and hospitalization (52% versus 22%, p<0.001). The First surge cases were older (28 +/- 18.8 years versus 18.8 +/- 11.1 years, p<0.001), had higher hemoglobin A1c (HbA1c) levels (Median (IQR): 9.3 (4.0) versus 8.4(2.8), <0.001) and use public insurance (n(%): 107 (57) versus 154 (38), p <0.001). There were five times increased odds of hospitalization for adults (OR 5.01 (2.11,12.63) in the first surge compared to the late surge. Conclusion COVID-19 cases among patients with T1D reported during the first surge had a higher proportion of adverse outcomes than those presented in a later surge.en-USPublisher PolicyCOVID-19type 1 diabetesSARS-CoV-2Article